Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors at 1 institution in 2 countries.
Mohamed KhassDivision of Clinical Immunology and Rheumatology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL, United States.
Michael LevinsonDivision of Clinical Immunology and Rheumatology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL, United States.
Robert L SchelonkaDivision of Neonatology, Department of Pediatrics, Oregon Health Science Center, Portland, OR, United States.
Pratibha KapoorDivision of Clinical Immunology and Rheumatology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL, United States.
Peter D BurrowsDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, AL, United States.
Harry W SchroederDivision of Clinical Immunology and Rheumatology, Department of Medicine, Microbiology, and Genetics, The University of Alabama at Birmingham, Birmingham, AL, United States.
University of Alabama at Birmingham · US
Funding
IMMUNOLOGIC DISEASES AND BASIC IMMUNOLOGYT32AI007051 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Laurie Ellen Harrington · 1985 to 2026
$13.1M
HLA Region and KIR Genomics in Common Variable Immune DeficiencyU01AI090902 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SCHROEDER, HARRY WILLIAM · 2010 to 2014
$2.9M
Role of VpreB in immunoglobulin antigen binding site selectionR21AI134027 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SCHROEDER, HARRY WILLIAM · 2018 to 2019
$408k
The pre-BCR CDR-H3 sensing site and H chain selectionR21AI117703 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SCHROEDER, HARRY WILLIAM · 2015 to 2016
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Preimmune Control of the Variance of TCR CDR-B3: Insights Gained From Germline Replacement of a TCR Dβ Gene Segment With an Ig D · full record | OpenQuestion